A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer. HCRN: LUN17-302

Learn more:

• clinicaltrials.gov: #NCT03913455
• News release